Davis, Tessa R.2023-01-182023-01-182023-01-18101 Or. L. Rev. 1370196-2043https://hdl.handle.net/1794/2792452 pagesThis Article considers how tax is poised to respond to CRISPR [Clustered Regularly Interspaced Short Palindromic Repeats] and similar emerging medical technologies with both therapeutic and so called enhancement applications. Doing so exposes gaps in current tax law as applied to the body and biotechnologies.en-USAll Rights Reserved.TaxationBiotechnologyTax lawArticle